Stock Analysis
Krystal Biotech, Inc. (KRYS) Stock Analysis
Krystal Biotech, Inc. (KRYS) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Krystal Biotech, Inc. (KRYS) currently has an AIQ Score of 69/100, indicating a bullish setup. Quality is the strongest factor at 83/100. Momentum is the weakest current factor at 58/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
KRYS at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $305.23 |
| AIQ Score | 69/100 |
| Overall View | Bullish |
| Technical Analysis Consensus | Strong Sell |
| Market Cap | $9.04B |
| P/E Ratio (TTM) | 39.85 |
| Forward P/E | — |
| EPS (Q3 FY2026) | $2.13 |
| Revenue (Q3 FY2026) | $127.34M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 0.74 |
| Volume | 110.29K |
| 52-week range | $198.02-$382.54 |
| RSI 14 | 43.03 |
| 50-Day SMA | $326.77 |
| 200-Day SMA | $309.71 |
| Analyst Price Target | $428.50 |
| Next Earnings | Feb 16, 2027 |
KRYSKrystal Biotech, Inc.
Healthcare / Biotechnology
Leader
Strong Relative Position
Latest quote
- Momentum58
- Value67
- Quality83
- Risk resilience69
- Sentiment—
KRYS Stock Analysis Summary
Krystal Biotech, Inc. (KRYS) currently has an AIQ Score of 69/100, indicating a bullish setup. Quality is the strongest factor at 83/100. Momentum is the weakest current factor at 58/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bullish regime, KRYS has AIQ Score of 69/100 with Quality base of 83/100 and fading Momentum at 58/100. Wait for component alignment before adding exposure.
Quality (83/100) leads while Momentum (58/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -0.15% stock move · KRYS classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is KRYS Bullish or Bearish Right Now?
KRYS currently has a bullish overall setup. Quality is the strongest factor at 83/100, while Momentum is weakest at 58/100. The current evidence suggests a constructive setup.
- - Quality is supportive at 83/100.
- - Risk Resilience is supportive at 69/100.
- - Analyst target implies +40.39% upside from the latest quote.
- - Price is -1.45% below its 200-day SMA.
- - Technical consensus has more sell votes than buy votes (33 vs 4).
Current Consensus
KRYS's Technical Analysis Consensus is currently Strong Sell, with 4 buy, 9 neutral, and 33 sell votes. KRYS's 14-day RSI is 43.03, which places the stock in a weaker momentum range. KRYS's beta is 0.74, indicating lower market sensitivity than the broad market.
What Changed in KRYS?
The largest recent change in KRYS is Momentum moving down by 8.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.
What Would Change the KRYS Outlook?
The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
KRYS Decision Framework
Public evidence layers, setup checks, and risk context for Krystal Biotech, Inc..
Krystal Biotech, Inc. (KRYS) Stock Analysis
Krystal Biotech, Inc. has an AIQ Score of 69/100 in a Bullish regime. Quality is strongest at 83/100. Beta is 0.74, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | KRYS is in a Bullish AIQ regime with score 69/100. |
| Signal Conflict | The primary conflict is that quality leads at 83/100 while momentum lags at 58/100. |
| Factor Evidence | Momentum 58/100 · Value 67/100 · Quality 83/100 · Risk 69/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Quality is the strongest factor at 83/100.
Momentum is 58/100 and RSI (14) is 43.0.
KRYS is in a Bullish regime at 69/100.
Risk factor is 69/100 with beta 0.74 and annual volatility 39.38%.
Current conflict: quality leads at 83/100 while momentum lags at 58/100.
KRYS Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
KRYS Fundamentals
KRYS valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
KRYS Technical Analysis
KRYS technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
KRYS Stock Catalysts
Track KRYS earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
KRYS Dividend Analysis
KRYS dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
KRYS Financial Data
KRYS revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
KRYS Risk Analysis
KRYS volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
KRYS Stock News
KRYS stock news, market tone, recent headlines, and catalyst context.
KRYS vs Biotechnology Peers
Current peer cohort: KRYS · KURA · KYMR · LGND · MAZE. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| KRYS Current stock | 69/100 | 67/100 | 58/100 | 69/100 | 1.16 | 39.38% | Current |
| KURA Kura Oncology, Inc. | 47/100 | 70/100 | 40/100 | 39/100 | -0.25 | 63.01% | KRYS vs KURA |
| KYMR Kymera Therapeutics, Inc. | 65/100 | 43/100 | 87/100 | 60/100 | 1.33 | 63.12% | KRYS vs KYMR |
| LGND Ligand Pharmaceuticals Incorporated | 76/100 | 61/100 | 86/100 | 70/100 | 1.25 | 36.55% | KRYS vs LGND |
| MAZE Maze Therapeutics, Inc. | 59/100 | 42/100 | 83/100 | 47/100 | 0.41 | 67.20% | KRYS vs MAZE |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for KRYS: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching KRYS
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for KRYS
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
KRYS Stock FAQ
What is KRYS stock price today?
Krystal Biotech, Inc.'s current stock price is $305.23. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is KRYS bullish or bearish right now?
KRYS's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is KRYS's market cap?
KRYS's market cap is $9.04B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is KRYS's current P/E ratio?
KRYS's current P/E ratio is 39.85 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is KRYS's RSI?
KRYS's 14-day RSI is 43.03 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is KRYS above its 50-day and 200-day moving averages?
KRYS is -6.59% from its 50-day SMA and -1.45% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is KRYS's next earnings date?
KRYS's next earnings date is currently listed as Feb 16, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does KRYS pay a dividend?
KRYS's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.